etrasimod (Velsipity)
Jump to navigation
Jump to search
Indications
- investigational treatment of atopic dermatitis
- ulcerative colitis (FDA-approved)
Contraindications
- myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or heart failure class III or IV
- history of Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker.
Dosage
Adverse effects
- may increase risk of infections
- unintended additive immune system effects from prior treatment with immunosuppressives or immunomodulators
- immune system effects after stopping etrasimod
- bradyarrhythmia & atrioventricular conduction delays
- hepatotoxicity: increase in serum transaminases
- may increase risk of macular edema
- hypertension
- skin cancer
- posterior reversible encephalopathy syndrome
- may cause a decline in pulmonary function[3]
Mechanism of action
- sphingosine 1-phosphate receptor 1 (S1PR1) modulator
- prevents immune cells or lymphocytes from getting into skin
More general terms
References
- ↑ Laub G Etrasimod Shows Promise for Atopic Dermatitis New safety and efficacy data highlight potential, Emma Guttman-Yassky explains. MedPage Today May 24, 2021 https://www.medpagetoday.com/meetingcoverage/aadvideopearls/92764
- ↑ Brooks M FDA Approves New Drug for Ulcerative Colitis. Medscape. Oct 13, 2023 https://www.medscape.com/viewarticle/997350
Sandborn WJ et al Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):P1159 April 8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36871574 Free article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00061-2/fulltext - ↑ 3.0 3.1 HIGHLIGHTS OF PRESCRIBING INFORMATION Velsipity. tablets, for oral use https://labeling.pfizer.com/ShowLabeling.aspx?id=19776